Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Nevro, Neutral and Piper Sandler
Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85
Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market capitalization of $214 million, to Neutral from Underweight and adjusted the price target to $5.
Nevro price target raised to $5.85 from $5 at Baird
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition
Nevro upgraded to Neutral from Underweight at Piper Sandler
Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company
Jefferies raises Nevro stock rating, boosts price target to $5.85
Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an increase to $5.85,
4h
Nevro Corp (NVRO) Receives a Hold from Wells Fargo
In a report released on February 7, Nathan Treybeck from Wells Fargo maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a ...
3d
Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...
Zacks.com on MSN
3d
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
MassDevice
3d
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
2d
Nevro upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
medtechdive
3d
Globus to buy Nevro for $250M
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
3d
Globus Medical to buy California life sciences firm for $250M
Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...
3d
Globus acquisition of Nevro ‘fairly low-risk bet,’ says BTIG
BTIG says Globus Medical’s (GMED) announced acquisition of Nevro (NVRO) “is surprising on the surface.” Investors did not expect Globus would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Globus Medical
New York Stock Exchange
NVRO
Piper Sandler
Feedback